Greece Widens Medical Cannabis Trials at ELGO-DIMITRA
Photo by Greece Newstart via Unsplash.
Drive about fifteen minutes east of Thessaloniki, past the airport and into the flat agricultural land around Thermi, and you will not find a glass-walled biotech campus or a venture-funded grow operation with a name like some kind of energy drink. You will find a modest genetics institute run by a government agricultural organization, growing rows of cannabis plants that look, from a distance, like nothing more than an unusually tall test plot of grain. That is where most of Greece's actual cannabis science has happened for the better part of a decade.
The Hellenic Agricultural Organization, known by its Greek acronym ELGO-DIMITRA, has spent nearly ten years quietly working out which cannabis varieties actually grow well in Greek soil, under Greek sun, with Greek rainfall patterns -- work that gets far less attention than the political debates over legalization but arguably matters more to whether Greece's cannabis industry survives contact with reality. Now that groundwork is colliding with policy. A draft law opened for public consultation in April 2026 proposes raising the legal THC threshold for cultivation from 0.2% to 0.3%, nudging Greek regulation into line with the wider EU hemp framework. It sounds like a rounding error. It is not. Greece is trying to build something durable here -- a Mediterranean cultivation and export base that can compete with Portugal, Spain, and the established players in medical cannabis supply -- and the fine print of THC limits, licensing calendars, and pharmaceutical standards will decide whether that ambition holds up.
The Institute Behind Greece's Cannabis Science
ELGO-DIMITRA is the body the Greek state has formally designated as the competent authority for evaluating cannabis varieties, and within that organization the work falls to a specific unit: the Institute of Genetic Improvement and Plant Genetic Resources, abbreviated IGB&PGR, based in Thermi just outside Thessaloniki. It is not a name that shows up in glossy investor decks, but it is the institution doing the unglamorous work that everything else in Greece's cannabis sector depends on.
The institute's mandate breaks down into three concrete tasks. First, it tests cannabis varieties -- mostly industrial hemp cultivars sourced from established European seed catalogs -- to see how they actually perform under Greek growing conditions, since a variety bred for Dutch or Polish climate doesn't necessarily behave the same way under Macedonian sun with Mediterranean rainfall patterns. Second, it is responsible for producing a cultivation guide for industrial cannabis, essentially a technical manual that gives Greek farmers a reference point for planting density, irrigation, harvest timing, and the other agronomic decisions that determine whether a crop is commercially viable. Third, and less discussed, it trains the field inspectors who go out and verify THC content on licensed farms -- the people whose job is to make sure what's growing in a given field actually matches what the license says should be growing there.
Experimental fields at the Thermi site have been running continuously since 2016, typically carrying somewhere between six and twelve varieties at a time under comparative trial conditions. This is applied agronomy, full stop -- not the kind of pharmaceutical research that produces patentable extraction methods or novel cannabinoid formulations. The goal has always been narrower and more practical: match existing genetics to Greek regional growing conditions so that when licensed cultivation scales up, growers aren't discovering basic agronomic problems for the first time with real money on the line.
What a Decade of Field Trials Actually Found
Bialobrzskie produced the highest biomass yield (up to ~82.5 t/ha) among the six cannabis varieties tested in the 2016-2018 trials, while Tygra yielded the least (~18.3 t/ha), showing over a fourfold difference across varieties.
The most detailed data to come out of the Thermi trials covers six varieties tracked closely between 2016 and 2018: Bialobrzskie, Fedora 17, Felina 32, Futura 75, Santhica 27, and Tygra -- all established European industrial hemp cultivars rather than exotic or novel breeding lines. Researchers weren't just checking whether these plants would survive; they were measuring how they'd perform as an actual commercial crop.
The biomass numbers alone tell you why variety selection isn't a minor detail. Depending on the cultivar and the specific growing conditions in a given trial year, biomass production ranged from as low as 18.3 tonnes per hectare up to 82.5 tonnes per hectare -- more than a fourfold spread. That's an enormous gap for a grower to absorb, and it means picking the wrong variety for a given plot of land isn't a rounding error, it's the difference between a crop that pencils out financially and one that doesn't come close.
Seed yield told a steadier story, clustering between 2.1 and 2.9 tonnes per hectare across the varieties tested -- a much tighter band that suggests seed production is somewhat less sensitive to the variety-by-climate interaction than fiber and biomass output is. Researchers weren't just logging tonnage, either. They tracked agronomic traits like plant height, flowering time, and disease resistance alongside cannabinoid content, building a fuller picture of how each cultivar behaves across a full growing season rather than just what it weighs at harvest.
The practical upshot for anyone thinking about commercial cultivation in Greece is straightforward: genetics matter enormously, and a decade of comparative data now exists to help growers avoid expensive guesswork. It's the kind of unsexy dataset that never makes headlines but ends up mattering more than almost anything else once actual money is riding on a harvest.
How Greece's Legal Framework Took Shape
Photo by Linda Gerbec via Unsplash.
Greece's legal cannabis framework didn't arrive in one piece -- it was built in layers, each one adding a new institutional actor with its own scope of authority. Medical cannabis use was legalized in 2017, opening the door for patients to access cannabis-based medicines under prescription. The following year, in 2018, Greece lifted cultivation and processing restrictions on high-THC cannabis specifically for licensed companies, which is the moment the country's medical cannabis cultivation industry technically became possible rather than purely theoretical.
The rule currently governing the system is a joint ministerial decision known by its reference number, KYA 1033/364487/B'/6021, dated December 31, 2020. That decision is the document that formally hands ELGO-DIMITRA its oversight role over variety evaluation and cultivation guidance, tying the Thermi institute's agronomic work directly into the state's licensing apparatus rather than leaving it as a standalone research exercise.
Under the current rules, cultivation licenses require THC content to stay below 0.2%, and the application window opens on January 1 of each year -- a fixed annual cycle rather than a rolling one, which shapes how growers and companies plan their planting seasons around the calendar rather than around market conditions. That 0.2% ceiling has become the de facto dividing line in Greek cannabis policy: crops that stay under it qualify as industrial hemp, while anything above it falls into the more tightly controlled licensed medical cannabis category with its own separate set of permits and oversight.
What this adds up to is a system with three distinct institutional layers working in sequence -- a research institute doing the agronomic groundwork, a ministry issuing and administering cultivation licenses, and a medicines regulator overseeing anything that becomes a pharmaceutical product. It's a structure built for caution rather than speed, and it's a large part of why Greek cannabis policy has moved deliberately rather than in the sudden bursts of legislative activity seen in some other EU markets.
The 2026 Draft Law and the Push to 0.3% THC
Photo by Kampus Production via Pexels.
In April 2026, Greece's Health Ministry opened a public consultation on a draft law that bundles cannabis regulation together with nicotine and tobacco policy, framing all three as part of a broader healthcare reform package. The consultation window was narrow -- it ran only through April 27, 2026 -- giving growers, medical cannabis companies, and public health groups a compressed period to submit input before the ministry moves toward a final text.
The central cannabis-related proposal in the draft is the THC threshold change: raising the permitted cultivation limit from 0.2% to 0.3%. That 0.1 percentage point shift matters because it would bring Greece into alignment with the broader EU hemp regulatory standard, which has already settled on 0.3% as the cultivation ceiling in a number of member states following changes to the EU's Common Agricultural Policy rules on hemp. Greece adopting the same figure removes a friction point for any grower or exporter trying to operate across borders within the EU, since a crop that's legal to cultivate in one country but technically over the limit in a neighboring one creates real logistical and legal headaches.
It's worth being clear about what this draft law is not. There is no accompanying decriminalization bill moving through the Greek Parliament alongside it -- this reform is aimed squarely at the cultivation and industrial side of the cannabis question, not at personal use or possession policy, which remains governed by separate and considerably stricter rules. The two tracks are not connected, and nothing in the current legislative pipeline suggests they will be merged.
What makes the package notable is the direction it pulls in on the consumer side. While the draft loosens the agricultural THC ceiling, it simultaneously tightens rules around tobacco and nicotine consumption in the same reform bundle. That pairing signals a fairly consistent philosophy from the ministry: expand and modernize the cultivation and industrial framework where Greece sees economic upside, while clamping down harder on consumption-side products where the public health concerns are more established and politically less contentious.
From Research Plots to Export Pipeline
Photo by Mark Stebnicki via Pexels.
The regulatory changes matter because there's now real commercial infrastructure waiting to make use of them. IA Agro, the company operating a cultivation facility based in Thermi -- the same area anchoring ELGO-DIMITRA's research work -- says its site is in the final completion and commissioning stages as of this reporting. Validation cultivation runs and initial production are expected to begin around mid-October 2026, which would mark the shift from a facility under construction to one actually growing product at commercial scale.
From there, the company's own timeline points to first commercial exports beginning in early 2027. That would put Greece in position to start competing directly with the EU's more established medical cannabis exporters -- countries like Portugal, which has built out a considerable head start in cultivation licensing and export infrastructure over the past several years. Whether Greece can close that gap depends heavily on execution during exactly this commissioning window.
Standing between any Greek-grown product and a pharmacy shelf is Greece's National Organisation for Medicines, known by its Greek acronym EOF, which applies pharmaceutical manufacturing and quality requirements that are frequently described as among the strictest in the EU. That's not incidental friction -- it's the same layered, cautious regulatory instinct that shaped the licensing system in the first place, now applied to the finished product rather than the raw crop.
The clearest illustration of how long this pipeline actually takes came on February 19, 2024, when the first medical cannabis product that was both grown and processed entirely within Greece finally reached a pharmacy shelf. Given that ELGO-DIMITRA's field trials at Thermi date back to 2016, that means roughly eight years separated the first experimental plots from the first domestically produced product a patient could actually fill a prescription for. It's a useful benchmark for anyone assuming the 2026 legal changes will translate quickly into shelf-ready exports -- the Greek system, so far, simply doesn't move that fast.
What stands out about Greece's approach, looking back over the last decade, is how little of it has been rushed. Nearly ten years of variety trials at a modest institute outside Thessaloniki preceded any serious commercial output, and even after cultivation licensing opened up in 2018, it took until February 2024 for a fully domestic product to reach a pharmacy shelf. That's not the timeline of a government chasing a green-rush headline. It's the timeline of a bureaucracy trying to get the agronomy and the pharmaceutical compliance right before letting the market run ahead of the science.
The shift from a 0.2% to a 0.3% THC threshold reads, on its face, like a technical footnote. But it's worth reading as a statement of intent: Greece isn't trying to carve out its own idiosyncratic regulatory path the way some countries have with novel THC caps or unusual licensing categories. It's aligning itself with the broader EU hemp framework, which suggests a government more interested in frictionless trade with other member states than in regulatory distinctiveness for its own sake.
Whether any of this adds up to Greece becoming a genuine Mediterranean cultivation and export hub is, at this point, less a research question than an execution question. The agronomic groundwork from Thermi is solid and well-documented. What remains uncertain is whether EOF's pharmaceutical standards -- deliberately among the strictest in the EU -- and IA Agro's commissioning schedule both hold through 2027 without the delays that have characterized nearly every prior stage of this program. Given the pattern so far, betting on an aggressive timeline seems unwise. Betting against Greece eventually getting there seems unwise too.
